Coronavirus channel feed

Covid-19 roundup: EU re­stric­tions al­ready hav­ing im­pact, Japan says; Mod­er­na seeks to up vial ca­pac­i­ty, sees Sin­ga­pore OK

5 years ago

EU mis­tak­en­ly leaves key parts of As­traZeneca Covid-19 con­tract unredact­ed, re­veal­ing costs and So­ri­ot's 'best-ef­fort' claim

5 years ago

Ea­ger to re­deem its Covid-19 vac­cine, As­traZeneca touts 82.4% ef­fi­ca­cy for 12-week dos­ing sched­ule — but will the FDA buy it?

5 years ago
R&D

Glax­o­SmithK­line dou­bles down on Cure­Vac's mR­NA tech, bets $180M on the hunt for next-gen vac­cine

5 years ago
Deals
Manufacturing

Pfiz­er pre­dicts a $15B avalanche of cash from its Covid-19 vac­cine in 2021 as the R&D team claims a big spike in the tri­al suc­cess rate

5 years ago

Covid-19 roundup: In­ter­im analy­sis sug­gests Russ­ian vac­cine is 91.6% ef­fec­tive; US inks big deal with Aus­tralian com­pa­ny for its at-home coro­n­avirus test

5 years ago

Ex­clu­sive: Johns Hop­kins pro­fes­sor and biotech col­leagues tout new tech to test Covid-19 vac­cine re­sponse

5 years ago
Manufacturing

Biotech part­ner drops Glax­o­SmithK­line’s ad­ju­vant as it moves Covid-19 vac­cine in­to PhII/III, cit­ing ‘man­u­fac­tur­ing con­sid­er­a­tions’

5 years ago
Deals

Covid-19 roundup: Bay­er ex­pands deal with Cure­Vac to pro­duce shots; UK or­ders more Val­ne­va vac­cines

5 years ago

Gates Foun­da­tion backs gene ther­a­py pi­o­neer­s' sec­ond-gen Covid-19 vac­cine

5 years ago

J&J her­alds 66% ef­fi­ca­cy for sin­gle-dose shot, but falls short of mR­NA ri­vals

5 years ago
Pharma

Covid-19 roundup: As­traZeneca gets EMA thumbs up for vac­cine amid bit­ter feud with EU; No­var­tis jumps in to man­u­fac­ture Pfiz­er/BioN­Tech vac­cine

5 years ago

No­vavax says its Covid-19 vac­cine proved 89.3% ef­fec­tive in UK tri­al in­clud­ing vari­ant — while South African re­sults slide low­er

5 years ago

Covid-19 roundup: Con­tro­ver­sy around colchicine per­co­lates af­ter study fail­ure; As­traZeneca's meet­ing with EU was 'con­struc­tive,' but did­n't solve much

5 years ago

'Bank of BAR­DA': In­ves­ti­ga­tion finds HHS raid­ed pan­dem­ic pre­pared­ness funds for decade be­fore Covid-19

5 years ago

As new Covid-19 task force gets un­der­way, threat looms of vac­cine, mon­o­clon­al an­ti­body-re­sis­tant vari­ants

5 years ago

Covid-19 roundup: EU and As­traZeneca trade blows over slow­downs; Un­usu­al unions pop up to test an­ti­bod­ies, vac­cines

5 years ago

Eli Lil­ly demon­strates that 2 an­ti­bod­ies beat 1 for guard­ing against se­vere Covid-19. But can that solve the first an­ti­body’s prob­lem amid slow up­take?

5 years ago

Covid-19 roundup: As­traZeneca, Pfiz­er come un­der fire for pro­duc­tion de­lays; Mod­er­na con­sid­ers third boost­er dose to squash new vari­ants

5 years ago

Re­gen­eron touts pos­i­tive pre­lim­i­nary im­pact of its Covid an­ti­body cock­tail, pre­vent­ing symp­to­matic in­fec­tions in high-risk group

5 years ago
R&D

Covid-19 roundup: Mod­er­na dou­bles down on Covid-19 with new boost­er tri­als; Aus­tralia plans do­mes­tic pro­duc­tion of As­traZeneca vac­cine amid dis­tri­b­u­tion lag

5 years ago

Mer­ck scraps Covid-19 vac­cine pro­grams af­ter they fail to mea­sure up on ef­fi­ca­cy in an­oth­er ma­jor set­back in the glob­al fight

5 years ago

Covid-19 roundup: Eu­rope to seek clar­i­fi­ca­tion on Pfiz­er/BioN­Tech de­lays; J&J pre­dicts 100M dos­es for US by April

5 years ago

Covid-19 roundup: Flood, dead­ly fire threat­en As­traZeneca vac­cine plants; Italy won­ders aloud if it can sue Pfiz­er for vac­cine short­falls

5 years ago
First page Previous page 34353637383940 Next page Last page
A service from the Financial Times